An Open-Label, Non-Comparative, Phase III Study of the Raf-Kinase Inhibitor BAY 43-9006 as a Subsequent to First-Line Therapy in Patients With Advanced Renal Cell Carcinoma
NCT ID: NCT00492986
Last Updated: 2014-12-30
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
1150 participants
INTERVENTIONAL
2005-10-31
2008-11-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The purpose of this study is to make sorafenib available for patients with advanced Renal Cell Carcinoma, who have failed prior systemic therapy for advanced disease (i.e. requiring second line treatment), and who do not have access to or are not eligible for other clinical trials with sorafenib and who may benefit from treatment with sorafenib.
Patients will be treated orally with 400 mg bid sorafenib on a continuous basis and as a single agent. Patients may continue treatment until Disease Progression, intolerable toxicity, the patients chooses to withdraw consent or the patient is unlikely to benefit any further from treatment.
Overall, participation in the study will help determine the following:
* Find out if patients receiving Sorafenib will live longer
* Find out if Sorafenib helps to slow the worsening of kidney cancer
* Find out if Sorafenib has an effect on the tumours
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Arm 1
Nexavar (Sorafenib, BAY43-9006)
Multikinase inhibitor: Sorafenib mono therapy 400 mg bid
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Nexavar (Sorafenib, BAY43-9006)
Multikinase inhibitor: Sorafenib mono therapy 400 mg bid
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* The male or female patient must be at least 18 years of age
* The patient must have advanced Renal Cell Carcinoma
* The patient must have failed at least one prior systemic established therapy for advanced RCC (e. g. IL-2, IFN-a), or must have been unable to tolerate systemic therapy for advanced RCC, or is deemed by the Investigator to be unsuited for systemic therapy for advanced RCC
* A patient, who has received prior systemic and local therapies, must have completely recovered from acute toxicity (i. e. resolved back to CTCAE Grade 1 or less, or is considered as not going to resolve), if any, prior to study entry
* The patient must be, in the Investigator's opinion, reasonably likely to benefit from treatment with BAY 43-9006 as a single agent
* The patient must have an Eastern Cooperative Oncology Group (ECOG) performance status of 0-2
* The patient will not require other systemic anti-cancer chemotherapy, immunotherapy (including monoclonal antibodies) or hormonal therapy, except for bisphosphonates while taking BAY 43-9006
* Both male and female patients must use adequate barrier birth control methods (oral contraceptives, injectable contraceptives, intrauterine devices, condoms, sterilization) during their participation in the protocol. The birth control methods must be used for 4 weeks for female patients and for 3 months for male patients after discontinuation of treatment with sorafenib
* For patients, who have had major surgery, the wound must be completely healed prior to receiving BAY 43-9006 treatment (4 weeks)
Exclusion Criteria
* Patients, who are eligible for or do have access to any other sorafenib clinical trial as to the knowledge of the Investigator
* Patients who have a life expectancy of less than 2 months
* Patients with metastatic brain or meningeal tumors
* Patients are excluded who require any of the following:
* Investigational drug therapy during the treatment with sorafenib or within 30 days prior to their first dose of sorafenib
* Concomitant Rifampicin
* Concomitant St. John's Wort (Hypericum perforatum) Warfarin is allowed; however, for patients receiving concomitant warfarin therapy close monitoring of Prothrombin Time (PT) should be performed (please note that no laboratory data are collected in this study)
* Women who are pregnant or breast-feeding. Women of childbearing potential must have a negative pregnancy test performed within seven days of the start of study drug (please note that no laboratory data are collected in this study)
* Patients with congestive heart failure greater than NYHA functional class II (symptomatic during ordinary activity)
* Patients with cardiac arrhythmias greater than Grade 1 NCI CTCAE, Version 3.0 (conduction abnormality and supraventricular arrhythmia present but patient is asymptomatic; intervention not indicated, palpitations present and QTc \> 0.45-0.47 second)
* Patients with active coronary artery disease or ischemia
* Patients with Child-Pugh class C hepatic impairment
* Patients with severe renal impairment (calculated creatinine clearance of \< 30 ml/min) or who require dialysis
* Patients with active uncontrolled hypertension
* Patients with recent or active bleeding diathesis
* Patients with any medical condition which could jeopardize their safety while taking an investigational drug
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Bayer
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Bayer Study Director
Role: STUDY_DIRECTOR
Bayer
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Bruxelles - Brussel, , Belgium
Leuven, , Belgium
Århus C, , Denmark
Bordeaux, , France
Lyon, , France
Villejuif, , France
München, Bavaria, Germany
Hamburg, City state of Hamburg, Germany
Darmstadt, Hesse, Germany
Düsseldorf, North Rhine-Westphalia, Germany
Koblenz, Rhineland-Palatinate, Germany
Mainz, Rhineland-Palatinate, Germany
Homburg, Saarland, Germany
Dresden, Saxony, Germany
Lübeck, Schleswig-Holstein, Germany
Berlin, State of Berlin, Germany
Milan, , Italy
Modena, , Italy
Pavia, , Italy
Perugia, , Italy
Reggio Emilia, , Italy
Amsterdam, , Netherlands
Warsaw, , Poland
Barcelona, Barcelona, Spain
Madrid, Madrid, Spain
Oviedo, Principality of Asturias, Spain
Gothenburg, , Sweden
Stockholm, , Sweden
Basel, Canton of Basel-City, Switzerland
Geneva, Canton of Geneva, Switzerland
London, London, United Kingdom
Glasgow, Stratchclyde, United Kingdom
Sutton, Surrey, United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
Click here to find information about studies related to Bayer Healthcare products conducted in Europe
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2005-002524-34
Identifier Type: EUDRACT_NUMBER
Identifier Source: secondary_id
11941
Identifier Type: -
Identifier Source: org_study_id